RT Journal Article
SR Electronic
T1 Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.05.22278483
DO 10.1101/2022.08.05.22278483
A1 Dennis Schaefer-Babajew
A1 Zijun Wang
A1 Frauke Muecksch
A1 Alice Cho
A1 Raphael Raspe
A1 Brianna Johnson
A1 Marie Canis
A1 Justin DaSilva
A1 Victor Ramos
A1 Martina Turroja
A1 Katrina G. Millard
A1 Fabian Schmidt
A1 Juan Dizon
A1 Irina Shimelovich
A1 Kai-Hui Yao
A1 Thiago Y. Oliveira
A1 Anna Gazumyan
A1 Christian Gaebler
A1 Paul D. Bieniasz
A1 Theodora Hatziioannou
A1 Marina Caskey
A1 Michel C. Nussenzweig
YR 2022
UL http://medrxiv.org/content/early/2022/08/10/2022.08.05.22278483.abstract
AB Feedback inhibition of humoral immunity by antibodies was initially documented in guinea pigs by Theobald Smith in 1909, who showed that passive administration of excess anti-Diphtheria toxin inhibited immune responses1. Subsequent work documented that antibodies can enhance or inhibit immune responses depending on antibody isotype, affinity, the physical nature of the antigen, and engagement of immunoglobulin (Fc) and complement (C’) receptors2, 3. However, little is known about how pre-existing antibodies might influence the subsequent development of memory B cells. Here we examined the memory B cell response in individuals who received two high-affinity IgG1 anti-SARS-CoV-2 receptor binding domain (RBD)-specific monoclonal antibodies, C144-LS and C135-LS, and subsequently two doses of a SARS-CoV-2 mRNA vaccine. The two antibodies target Class 2 and 3 epitopes that dominate the initial immune response to SARS-CoV-2 infection and mRNA vaccination4–8. Antibody responses to the vaccine in C144-LS and C135-LS recipients produced plasma antigen binding and neutralizing titers that were fractionally lower but not statistically different to controls. In contrast, memory B cells enumerated by flow cytometry after the second vaccine dose were present in higher numbers than in controls. However, the memory B cells that developed in antibody recipients differed from controls in that they were not enriched in VH3-53, VH1-46 and VH3-66 genes and predominantly expressed low-affinity IgM antibodies that carried small numbers of somatic mutations. These antibodies showed altered RBD target specificity consistent with epitope masking, and only 1 out of 77 anti-RBD memory antibodies tested neutralized the virus. The results indicate that pre-existing high-affinity antibodies bias memory B cell selection and have a profound effect on the development of immunological memory in humans that may in part explain the shifting target profile of memory antibodies elicited by the 3rd mRNA vaccine dose.Competing Interest StatementThe Rockefeller University has filed a provisional patent application in connection with this work on which M.C.N. is an inventor (US patent 63/021,387).Funding StatementThis work was supported by NIH grants P01AI138398S1 and 2U19AI111825 to M.C.N., R37AI64003 to P.D.B. and R01AI78788 to T.H., and 3UM1AI1266205S1 to M. Caskey. D.S.B. is supported in part by the National Center for Advancing Translational Sciences (NIH Clinical and Translational Science Award program, grant UL1TR001866) and the Shapiro Silverberg Fund for the Advancement of Translational Research. F.M. was supported by the Bulgari Women & Science Fellowship in COVID 19 Research. P.D.B. and M.C.N. are Howard Hughes Medical Institute (HHMI)InvestigatorsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of The Rockefeller University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.